Literature DB >> 22456999

Family history of malignant and benign thyroid diseases and risk of thyroid cancer: a population-based case-control study in New Caledonia.

Christophe Leux1, Thérèse Truong, Claire Petit, Dominique Baron-Dubourdieu, Pascal Guénel.   

Abstract

PURPOSE: Exceptionally high incidence rates of thyroid cancer have been observed in New Caledonia, particularly in Melanesian women, but familial aggregation of thyroid diseases in this population is unknown. We study the association between family history of malignant or benign thyroid diseases and non-medullary thyroid cancer in this country.
METHODS: We conducted a population-based case-control study including 332 cases with papillary or follicular carcinoma diagnosed in 1993-1999 and 412 controls, matched by sex and 5-year age-group.
RESULTS: Thyroid cancer was associated with a history of thyroid cancer in first-degree relatives (odds ratio (OR), 3.2; 95 % CI, 1.6-6.2) and with a family history of multinodular goiter (OR, 3.6; 95 % CI, 1.9-7.0). The ORs did not change by age at diagnosis and with the number of affected relatives. The study provides evidence that the familial component of thyroid cancer is particularly strong in men. Thyroid cancer was not associated with a family history of thyroid diseases in Melanesians from the Loyalty Islands, the area with the highest incidence rates for thyroid cancer, possibly indicating a high frequency of genetic susceptibility variants and lack of genetic variation in this population subgroup.
CONCLUSION: Overall our findings confirm an elevated risk of thyroid cancer in individuals with a family history of malignant or benign thyroid diseases, particularly in Melanesians where familial aggregation of thyroid cancer had never been investigated before. The study of genetic variants in candidate susceptibility genes for thyroid cancer may help clarifying the absence of an association in the subgroup of Melanesians from the Loyalty Islands.

Entities:  

Mesh:

Year:  2012        PMID: 22456999     DOI: 10.1007/s10552-012-9944-7

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  10 in total

1.  Are the SNPs of NKX2-1 associated with papillary thyroid carcinoma in the Han population of Northern China?

Authors:  Lizhe Ai; Yaqin Yu; Xiaoli Liu; Chong Wang; Jieping Shi; Hui Sun; Qiong Yu
Journal:  Front Med       Date:  2014-01-23       Impact factor: 4.592

Review 2.  An update on familial nonmedullary thyroid cancer.

Authors:  Sabrine A Ammar; Wilson M Alobuia; Electron Kebebew
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

3.  Results of Screening in Familial Non-Medullary Thyroid Cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Lily Yang; Roxanne Merkel; Dhaval Patel; Naris Nilubol; Maria J Merino; Monica Skarulis; Samira M Sadowski; Electron Kebebew
Journal:  Thyroid       Date:  2017-07-19       Impact factor: 6.568

4.  Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

Authors:  Mustapha El Lakis; Andreas Giannakou; Pavel J Nockel; Douglas Wiseman; Sudheer Kumar Gara; Dhaval Patel; Zahraa Abdul Sater; Yevgeniya Y Kushchayeva; Joanna Klubo-Gwiezdzinska; Naris Nilubol; Maria J Merino; Electron Kebebew
Journal:  Surgery       Date:  2018-10-14       Impact factor: 3.982

5.  CCND1 gene polymorphic variants in patients with differentiated thyroid carcinoma.

Authors:  Szymon Hryhorowicz; Katarzyna Ziemnicka; Marta Kaczmarek-Ryś; Justyna Hoppe-Gołębiewska; Andrzej Pławski; Marzena Skrzypczak-Zielińska; Małgorzata Szkudlarek; Monika Gołąb; Bartłomiej Budny; Marek Ruchała; Ryszard Słomski
Journal:  Oncol Lett       Date:  2014-10-15       Impact factor: 2.967

Review 6.  Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis.

Authors:  Lihong Cao
Journal:  World J Surg Oncol       Date:  2018-09-10       Impact factor: 2.754

7.  Downregulated LRRK2 gene expression inhibits proliferation and migration while promoting the apoptosis of thyroid cancer cells by inhibiting activation of the JNK signaling pathway.

Authors:  Zheng-Cai Jiang; Xiao-Jun Chen; Qi Zhou; Xiao-Hua Gong; Xiong Chen; Wen-Jun Wu
Journal:  Int J Oncol       Date:  2019-05-29       Impact factor: 5.650

8.  Association Analysis of MET Gene Polymorphism with Papillary Thyroid Carcinoma in a Chinese Population.

Authors:  Lifeng Ning; Yaqin Yu; Xiaoli Liu; Lizhe Ai; Xin Zhang; Wenwang Rao; Jieping Shi; Hui Sun; Qiong Yu
Journal:  Int J Endocrinol       Date:  2015-11-15       Impact factor: 3.257

9.  Long noncoding RNA are aberrantly expressed in human papillary thyroid carcinoma.

Authors:  Meiliu Yang; Jinli Tian; Xin Guo; Ying Yang; Ruhua Guan; Mingyue Qiu; Yukai Li; Xueling Sun; Yanfeng Zhen; Yazhong Zhang; Chunyou Chen; Yanbing Li; Hui Fang
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

10.  Microarray-based differential expression profiling of long noncoding RNAs and messenger RNAs in formalin-fixed paraffin-embedded human papillary thyroid carcinoma samples.

Authors:  Hui-Xian Yan; Jin Du; Jing Fu; Wei Huang; Li-Meng Jia; Pang Ping; Ling Zhao; Ye-Qiong Song; Xiao-Meng Jia; Jing-Tao Dou; Yi-Ming Mu; Fu-Lin Wang; Wen Tian; Zhao-Hui Lyu
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.